CM/PHR/22/5687 - NHS National Proprietary Low Molecular Weight Heparins

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Contract (Products)
Duration
2 year
Value
£187M
Sector
HEALTH
Published
10 Aug 2023
Delivery
01 Sep 2023 to 31 Aug 2025
Deadline
03 May 2023 12:00

Concepts

Location

Geochart for 1 buyers and 8 suppliers

1 buyer

8 suppliers

Description

NHS National Framework for low molecular weight heparin products and fondaparinux Offer reference number: CM/PHR/22/5687 Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Award Detail

1 Drreddys Laboratories (Cambridge)
  • Value: £186,609,000
2 Pfizer (Tadworth)
  • Value: £186,609,000
3 Techdow Pharma England (Guildford)
  • Value: £186,609,000
4 Aventis Pharma (Reading)
  • Value: £186,609,000
5 Tetris Pharma (Marlow)
  • Value: £186,609,000
6 Mylan (Hatfield)
  • Value: £186,609,000
7 Rovi Biotech (Calle Jose Isbert)
  • Value: £186,609,000
8 Leo Pharma (Maidenhead)
  • Value: £186,609,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

Document No. 03 - Framework Agreement and Terms and Conditions - CM-PHR-22-5687 Document No. 03 - Framework Agreement and Terms and Conditions - CM-PHR-22-5687.docx Document No. 09 - Participating Authorities - CM-PHR-22-5687 Document No. 09 - Participating Authorities - CM-PHR-22-5687.xls FTS Opportunity Notice - LMWH - CM-PHR-22-5687 - 009091-2023 FTS Opportunity Notice - LMWH - CM-PHR-22-5687 - 009091-2023.pdf FTS Opportunity Notice F14 - LMWH - CM-PHR-22-5687 - 010173-2023 FTS Opportunity Notice F14 - LMWH - CM-PHR-22-5687 - 010173-2023.pdf Parties Appointed to the framework CM-PHR-22-5687 Parties Appointed to the framework CM-PHR-22-5687.xlsx Transparency Documents - LMWH - 5687 Transparency Documents - LMWH - 5687.pdf

Reference

Domains